PDCD1 and non-small cell lung carcinoma: With the development of immunotherapy, immune checkpoint inhibitors such as programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) antibodies have gradually become the standard treatment in patients with advanced NSCLC (5).